{"groups":[{"description":"PREPARATIVE REGIMEN\\*: Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. Patients also undergo helical tomotherapy twice daily on days -7 to -4. TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. NOTE: \\*Treatment begins 2 days earlier in patients receive tacrolimus and/or sirolimus for GVHD prophylaxis.\n\nfludarabine phosphate: 25 mg/m2 day -7 through day -3 prior to transplant\n\nmelphalan: 140 mg/m2 day -2 prior to transplant\n\nallogeneic hematopoietic stem cell transplantation: Cells infused on Day 0 of transplant regimen\n\nintensity-modulated radiation therapy: Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant","id":"FG000","title":"Treatment (Enzyme Inhibitor, Radiation Therapy, Transplant)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"62"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"62"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Among the 75 patients, who consented to the study, 13 of them became ineligible after screening. So only 62 patients received the study treatment."}